Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The Consensus Coding Sequences of Human Breast and Colorectal Cancers.Science. 2006; 314: 268-274
- General lessons from large-scale studies to identify human cancer predisposition genes.J Pathol. 2010; 220: 255-262
- Adjuvant Chemotherapy for Breast Cancer.JAMA. 1985; 254: 3461-3463
- Treatment of Primary Breast Cancer with Chemotherapy and Tamoxifen.N Engl J Med. 1981; 305: 1-6
- A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive Tumors.N Engl J Med. 1989; 320: 479-484
- Recombinant Humanized Anti-HER2 Antibody (Herceptin™) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts1.Cancer Res. 1998; 58: 2825-2831
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease.J Clin Oncol. 1999; 17: 2639
- Molecular portraits of human breast tumours.Nature. 2000; 406: 747-752
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer.N Engl J Med. 2004; 351: 2817-2826
- Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.CA Cancer J Clin. 2017; 67: 290-303
- Gene expression profiling predicts clinical outcome of breast cancer.Nature. 2002; 415: 530-536
- A Gene-Expression Signature as a Predictor of Survival in Breast Cancer.N Engl J Med. 2002; 347: 1999-2009
- Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens.BMC Cancer. 2014; 14: 177
- Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.BMC Med Genomics. 2015; 8: 54
- Supervised risk predictor of breast cancer based on intrinsic subtypes.J Clin Oncol. 2009; 27: 1160-1167
- A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.Clin Cancer Res. 2011; 17: 6012-6020
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.N Engl J Med. 2015; 373: 2005-2014
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.N Engl J Med. 2018; 379: 111-121
- Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.JAMA Oncol. 2020; 6: 367-374
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.N Engl J Med. 2021; 385: 2336-2347
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®); Guideline Breast Cancer 4.2022. National Comprehensive Cancer Network, Inc. 2022.
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.N Engl J Med. 2016; 375: 717-729
- 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.Lancet Oncol. 2021; 22: 476-488
- Computer Program to Assist in Making Decisions About Adjuvant Therapy for Women With Early Breast Cancer.J Clin Oncol. 2001; 19: 980-991
- Sequencing technologies - the next generation.Nat Rev Genet. 2010; 11: 31-46
- Whole-genome analysis informs breast cancer response to aromatase inhibition.Nature. 2012; 486: 353-360
- Activating HER2 mutations in HER2 gene amplification negative breast cancer.Cancer Discov. 2013; 3: 224-237
- Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer.Front Oncol. 2017; 7: 26
- Characterizing Molecular Variants and Clinical Utilization of Next-generation Sequencing in Advanced Breast Cancer.Appl Immunohistochem Mol Morphol. 2017; 25: 392-398
- Clinical Outcomes of Molecular Tumor Boards: A Systematic Review.JCO Precis Oncol. 2021; (5doi:)https://doi.org/10.1200/PO.20.00495
- Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.Breast Cancer Res Treat. 2018; 168: 159-168
- Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.Genome Med. 2016; 8: 109
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.Nat Biotechnol. 2013; 31: 1023-1031
- Comprehensive molecular profiling broadens treatment options for breast cancer patients.Cancer Med. 2021; 10: 529-539
- Targeted mutation detection in breast cancer using MammaSeq.Breast Cancer Res. 2019; 21: 22
- Subclonal diversification of primary breast cancer revealed by multiregion sequencing.Nat Med. 2015; 21: 751-759
- Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization.Clin Chem. 2015; 61: 64-71
- Clinical trials of precision medicine through molecular profiling: focus on breast cancer.Am Soc Clin Oncol Educ Book. 2015; 35: e183-e190
- A sample preparation and analysis system for identification of circulating tumor cells.J Clin Ligand Assay. 2002; 25: 104-110
- Challenges in circulating tumor cell detection by the CellSearch system.Mol Oncol Mar. 2016; 10: 395-407
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer.N Engl J Med. 2004; 351: 781-791
- Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer.J Clin Oncol. 2005; 23: 1420-1430
- Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.Lancet Oncol. 2014; 15: 406-414
- Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy.J Natl Cancer Inst. 2021; 113: 443-452
- Detection of cancer before distant metastasis.BMC Cancer. 2013; 13: 283
- Prenatal Diagnosis Innovation: Genome Sequencing of Maternal Plasma.Annu Rev Med. 2016; 67: 419-432
- Liquid biopsies come of age: towards implementation of circulating tumour DNA.Nat Rev Cancer. 2017; 17: 223-238
- Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: A qualitative study.Gene. 2016; 590: 142-148
- Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.Nat Commun. 2015; 6: 8760
- Circulating Cell-Free DNA Captures the Intratumor Heterogeneity in Multinodular Hepatocellular Carcinoma.JCO Precis Oncol. 2022; 6: e2100335
- Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.Sci Transl Med. 2015; 7: 302ra133
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.Nature. 2017; 545: 446-451
- Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy.Mol Oncol. 2020; 14: 1719-1730
- Detection and localization of surgically resectable cancers with a multi-analyte blood test.Science. 2018; 359: 926-930
- Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA.Ann Oncol. 2020; 31: 745-759
- Cell-free DNA TAPS provides multimodal information for early cancer detection.Sci Adv. 2021; 7: eabh0534
- Genome-wide cell-free DNA fragmentation in patients with cancer.Nature. 2019; 570: 385-389
- Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy.NPJ Breast Cancer. 2017; 3: 24
- Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.JAMA Oncol. 2019; 5: 1473-1478
- Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer.Sci Transl Med. 2019; 11https://doi.org/10.1126/scitranslmed.aax7392
Article info
Publication history
Published online: October 17, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
